Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir Phase 3 post-exposure prevention study in adults
PACTR202203593113347Phase 3Completed
- Sponsor
- MSD
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of molnupiravir in coronavirus disease 2019 (COVID-19), sponsored by MSD. Primary endpoint: Proportion of participants developing COVID-19 through Day 14. Started Aug 2021; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202203593113347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202203593113347.